Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies

BACKGROUND AND AIMS: Analyses of Crohn’s Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, Remo, Löfberg, Robert, Rutgeerts, Paul, Sandborn, William J, Schreiber, Stefan, Berg, Sofie, Maa, Jen-Fue, Petersson, Joel, Robinson, Anne M, Colombel, Jean-Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535500/
https://www.ncbi.nlm.nih.gov/pubmed/30753371
http://dx.doi.org/10.1093/ecco-jcc/jjy223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535500/
https://www.ncbi.nlm.nih.gov/pubmed/30753371
http://dx.doi.org/10.1093/ecco-jcc/jjy223

Ejemplares similares